Rapid Low Cost Urine Test Diagnoses Tuberculosis, Reduces Mortality
By LabMedica International staff writers Posted on 21 Mar 2016 |
A low cost, easy to use, urine test to diagnose tuberculosis (TB) among patients with human immunodeficiency virus (HIV) could help reduce the TB death rate of HIV-positive patients in hospital.
HIV-associated tuberculosis is difficult to diagnose and results in high mortality and frequent extra-pulmonary presentation, inability to obtain sputum, and paucibacillary samples limits the usefulness of nucleic-acid amplification tests and smear microscopy.
A team of international scientists led by those at the University of Cape Town (South Africa) randomly allocated 2,528 patients with HIV from 10 hospitals in four countries in sub-Saharan Africa (four in South Africa, two in Tanzania, two in Zambia, and two in Zimbabwe) to receive either routine testing including smear, Xpert MTP/RIF (Cepheid, Sunnyvale , CA, USA) and culture, as well as the LAM urine-test (LAM group, 1,257 patients) or routine testing alone (no-LAM group, 1,271 patients).
All patients were asked to provide a urine sample of at least 30 mL at enrolment, and trained research nurses did the LAM test in patients allocated to this group using the Alere Determine tuberculosis LAM Ag lateral flow strip test (Alere; Waltham, MA, USA) at the bedside on enrolment. The LAM urine-test detects a glycolipid molecule (lipoarabinomannan), which is linked to TB. It provides a result in 25 minutes and each test costs about USD 2.66.
Eight weeks after being discharged from hospital, 21% (261) of patients in the LAM group had died compared to 25% (317) of patients in the non-LAM group, an absolute reduction of 4%. A greater proportion of patients in the LAM group (648; 52%) were treated for TB than in the no-LAM group (598; 47%). Those who started TB treatment, a higher proportion of patients were treated in the first three days in the LAM group (513/648; 79%) compared to the non-LAM group (413/598; 69%).
The effect of LAM testing on mortality varied by country but the highest sensitivity was found in people with the lowest CD4 cell count, a measure of how badly the immune system is damaged in patients with HIV, who are the hardest to diagnose with TB using routine testing. The authors found that the LAM urine-test had a sensitivity of 46% (the proportion of people with TB correctly diagnosed) and specificity of 90% (the proportion of healthy people who are correctly identified as healthy). The study was published on March 9, 2016, in the journal the Lancet.
Related Links:
University of Cape Town
Cepheid
Alere
HIV-associated tuberculosis is difficult to diagnose and results in high mortality and frequent extra-pulmonary presentation, inability to obtain sputum, and paucibacillary samples limits the usefulness of nucleic-acid amplification tests and smear microscopy.
A team of international scientists led by those at the University of Cape Town (South Africa) randomly allocated 2,528 patients with HIV from 10 hospitals in four countries in sub-Saharan Africa (four in South Africa, two in Tanzania, two in Zambia, and two in Zimbabwe) to receive either routine testing including smear, Xpert MTP/RIF (Cepheid, Sunnyvale , CA, USA) and culture, as well as the LAM urine-test (LAM group, 1,257 patients) or routine testing alone (no-LAM group, 1,271 patients).
All patients were asked to provide a urine sample of at least 30 mL at enrolment, and trained research nurses did the LAM test in patients allocated to this group using the Alere Determine tuberculosis LAM Ag lateral flow strip test (Alere; Waltham, MA, USA) at the bedside on enrolment. The LAM urine-test detects a glycolipid molecule (lipoarabinomannan), which is linked to TB. It provides a result in 25 minutes and each test costs about USD 2.66.
Eight weeks after being discharged from hospital, 21% (261) of patients in the LAM group had died compared to 25% (317) of patients in the non-LAM group, an absolute reduction of 4%. A greater proportion of patients in the LAM group (648; 52%) were treated for TB than in the no-LAM group (598; 47%). Those who started TB treatment, a higher proportion of patients were treated in the first three days in the LAM group (513/648; 79%) compared to the non-LAM group (413/598; 69%).
The effect of LAM testing on mortality varied by country but the highest sensitivity was found in people with the lowest CD4 cell count, a measure of how badly the immune system is damaged in patients with HIV, who are the hardest to diagnose with TB using routine testing. The authors found that the LAM urine-test had a sensitivity of 46% (the proportion of people with TB correctly diagnosed) and specificity of 90% (the proportion of healthy people who are correctly identified as healthy). The study was published on March 9, 2016, in the journal the Lancet.
Related Links:
University of Cape Town
Cepheid
Alere
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia